Abstract
Most drugs with central nervous system (CNS) activity enter the brain either by diffusing across the membranes which comprise the blood-brain barrier (BBB) or by being transported by carrier systems across those membranes. Substances which cannot cross the BBB by one of these mechanisms, like serum albumin, are virtually excluded from the CNS. However, this exclusion is not absolute. Cerebrospinal fluid (CSF) levels of albumin, for example, are about 0.5% those of serum levels. Albumin enters the CNS through a variety of pathways collectively termed the extracellular pathways. Any circulating substance can, in theory, use these pathways to enter the CNS. But, traditional drug development has ignored this pathway. To approach even the CSF / serum ratio of 0.5%, a candidate therapeutic would need to meet several criterion: long half-life in blood, small volume of distribution, high potency in the CNS, and absence of brain-to-blood efflux. Two emerging therapeutics which are likely exerting their CNS effects by way of the extracellular pathways are antibodies directed against amyloid beta protein (ABP) and erythropoietin (Epo) used in the treatment of stroke. These examples suggest that the extracellular pathways are an option for the delivery of certain therapeutics to the brain.
Keywords: central nervous system, blood-brain barrier, amyloid beta protein, erythropoietin
Current Pharmaceutical Design
Title: Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?
Volume: 10 Issue: 12
Author(s): William A. Banks
Affiliation:
Keywords: central nervous system, blood-brain barrier, amyloid beta protein, erythropoietin
Abstract: Most drugs with central nervous system (CNS) activity enter the brain either by diffusing across the membranes which comprise the blood-brain barrier (BBB) or by being transported by carrier systems across those membranes. Substances which cannot cross the BBB by one of these mechanisms, like serum albumin, are virtually excluded from the CNS. However, this exclusion is not absolute. Cerebrospinal fluid (CSF) levels of albumin, for example, are about 0.5% those of serum levels. Albumin enters the CNS through a variety of pathways collectively termed the extracellular pathways. Any circulating substance can, in theory, use these pathways to enter the CNS. But, traditional drug development has ignored this pathway. To approach even the CSF / serum ratio of 0.5%, a candidate therapeutic would need to meet several criterion: long half-life in blood, small volume of distribution, high potency in the CNS, and absence of brain-to-blood efflux. Two emerging therapeutics which are likely exerting their CNS effects by way of the extracellular pathways are antibodies directed against amyloid beta protein (ABP) and erythropoietin (Epo) used in the treatment of stroke. These examples suggest that the extracellular pathways are an option for the delivery of certain therapeutics to the brain.
Export Options
About this article
Cite this article as:
Banks A. William, Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384862
DOI https://dx.doi.org/10.2174/1381612043384862 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Neurosarcoidosis
Current Neuropharmacology Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Transmucosal Drug Delivery- An Overview
Drug Delivery Letters Role of Old Antibiotics in Multidrug Resistant Bacterial Infections
Current Drug Targets Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Brain-metastatic Breast Cancer: Clinical Considerations and Pharmacological Approaches
Anti-Cancer Agents in Medicinal Chemistry The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design Clinical and Translational Research Challenges in Biliary Tract Cancers
Current Medicinal Chemistry Ion Transporters in Brain Tumors
Current Medicinal Chemistry The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics Gene Therapy of Chronic Pain
Current Gene Therapy Aquaporins and Glia
Current Neuropharmacology Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Current Pharmaceutical Design Coexistence of Ectopic Posterior Pituitary and Sellar/Suprasellar Arachnoid Cyst: A Case Report
Current Medical Imaging Intracranial Cerebrospinal Fluid Volume Evaluation in Healthy People and Hydrocephalus Patients using SPACE Sequence
Current Medical Imaging